Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 19INDUSTRY 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × trilaciclib × Clear all
NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Henan Cancer Hospital

Phase 2 Enrolling by invitation
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡